Texte AlternatifThe spread of the coronavirus has refocused the world’s attention on proper care of the supply chain for vaccines and drugs. Additionally, interest has surged in low-cost technology that monitors the cold chain, identifies temperature abuse and tampering and provides authentication.

Bisphenol A (BPA) has been labeled “an endocrine disruptor,” though it is found in many plastics, the lining of food and beverage cans and carbonless paper. Several companies have attempted to limit Bisphenol A, F and S in order to be more cautious. CTI recognized that effort and has responded with its latest innovation now available to pharmaceutical packaging companies.

CTI’s BlindSpotz™ technology is a portfolio of patented technology that created low-cost printable sensors for drugs that detects freezing, thawing, gradual warming, tampering and authentication. Pharmaceutical printers, as well as food and beverage printers, are requiring CTI’s innovative thermochromic inks to be free of Bisphenol A, F and S. Heretofore, printers have rejected traditional thermochromics for not meeting strict internal and external regulatory standards.

“We undertook the challenge of reinventing thermochromic technology to meet the high standards of pharmaceutical customers,” said Lyle Small, CTI’s chief executive officer. “Not only did we create CTI’s products free of BPA, F and S, but we also installed a 21-step checklist to validate quality and performance”.

All rights reserved except agreement written by Emballage Digest or mention of the magazine